Am J Perinatol 2011; 28(7): 571-578
DOI: 10.1055/s-0031-1274511
© Thieme Medical Publishers

Caffeine and Insulin Resistance in Pregnancy

S. Katherine Laughon1 , Robert W. Powers1 , James M. Roberts1 , 2 , 3 , 4 , Sarah Parana4 , Janet Catov1 , 2 , 4
  • 1Department of Obstetrics, Gynecology and Reproductive Services, Pittsburgh, Pennsylvania
  • 2Department of Epidemiology, Pittsburgh, Pennsylvania
  • 3Department of Clinical and Translational Research Institute University of Pittsburgh, Pittsburgh, Pennsylvania
  • 4Department of Magee-Womens Research Institute, Pittsburgh, Pennsylvania
Further Information

Publication History

Publication Date:
04 March 2011 (online)

ABSTRACT

Outside pregnancy, acute caffeine consumption is associated with insulin resistance. We investigated if during pregnancy plasma concentrations of caffeine and its metabolite, paraxanthine, were associated with insulin resistance. Caffeine, paraxanthine, glucose, and insulin were measured and insulin resistance estimated by homeostasis model assessment (HOMA) in banked samples from 251 fasting subjects at mean gestational age of 20.3 ± 2.0 weeks. Analysis of covariance and adjusted logistic regression were performed. Most (96.4%) women had caffeine and/or paraxanthine present. Caffeine concentrations in the upper two quartiles (>266 ng/mL) were associated with threefold higher odds of having higher insulin resistance estimated by log HOMA ≥75th percentile (third quartile odds ratio [OR], 3.02; 95% confidence interval [CI]: 1.21 to 7.54 and fourth quartile OR, 2.95; 95% CI: 1.19 to 7.31). Paraxanthine concentrations in the upper quartile (>392 ng/mL) were also associated with threefold higher odds of having higher insulin resistance (OR, 3.04; 95% CI: 1.28 to 7.25). Adjusted mean HOMA in the first caffeine-to-paraxanthine ratio quartile was 1.5 ± 2.2 versus 1.3 ± 2.3 in the fourth quartile (p < 0.01). Both high caffeine and paraxanthine concentrations were associated with insulin resistance, but slow versus fast metabolism did not make an important difference.

REFERENCES

  • 1 Frary C D, Johnson R K, Wang M Q. Food sources and intakes of caffeine in the diets of persons in the United States.  J Am Diet Assoc. 2005;  105 110-113
  • 2 Eskenazi B. Caffeine—filtering the facts.  N Engl J Med. 1999;  341 1688-1689
  • 3 Robinson L E, Savani S, Battram D S, McLaren D H, Sathasivam P, Graham T E. Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes.  J Nutr. 2004;  134 2528-2533
  • 4 Petrie H J, Chown S E, Belfie L M et al.. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss.  Am J Clin Nutr. 2004;  80 22-28
  • 5 Keijzers G B, De Galan B E, Tack C J, Smits P. Caffeine can decrease insulin sensitivity in humans.  Diabetes Care. 2002;  25 364-369
  • 6 Lane J D, Barkauskas C E, Surwit R S, Feinglos M N. Caffeine impairs glucose metabolism in type 2 diabetes.  Diabetes Care. 2004;  27 2047-2048
  • 7 Pizziol A, Tikhonoff V, Paleari C D et al.. Effects of caffeine on glucose tolerance: a placebo-controlled study.  Eur J Clin Nutr. 1998;  52 846-849
  • 8 Thong F S, Graham T E. Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans.  J Appl Physiol. 2002;  92 2347-2352
  • 9 Thong F S, Derave W, Kiens B et al.. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise.  Diabetes. 2002;  51 583-590
  • 10 Avogaro A, Toffolo G, Valerio A, Cobelli C. Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. A stable label intravenous glucose tolerance test minimal model study.  Diabetes. 1996;  45 1373-1378
  • 11 Lane J D. Caffeine may raise insulin resistance in prediabetics.  ObGynNews. 2007;  (June 1) 36
  • 12 van Dam R M, Hu F B. Coffee consumption and risk of type 2 diabetes: a systematic review.  JAMA. 2005;  294 97-104
  • 13 Wolf M, Sandler L, Jimenez-Kimble R, Shah A, Ecker J L, Thadhani R. Insulin resistance but not inflammation is associated with gestational hypertension.  Hypertension. 2002;  40 886-891
  • 14 Wolf M, Sandler L, Muñoz K, Hsu K, Ecker J L, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study.  J Clin Endocrinol Metab. 2002;  87 1563-1568
  • 15 Hadden D R. Prediabetes and the big baby.  Diabet Med. 2008;  25 1-10
  • 16 Robinson L E, Spafford C, Graham T E, Smith G N. Acute caffeine ingestion and glucose tolerance in women with or without gestational diabetes mellitus.  J Obstet Gynaecol Can. 2009;  31 304-312
  • 17 Adeney K L, Williams M A, Schiff M A, Qiu C, Sorensen T K. Coffee consumption and the risk of gestational diabetes mellitus.  Acta Obstet Gynecol Scand. 2007;  86 161-166
  • 18 Daly J. Caffeine, coffee and health. In: Garattini S, ed. Mechanism of Action of Caffeine. New York: Raven Press; 1993: 97-149
  • 19 Grosso L M, Bracken M B. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy.  Ann Epidemiol. 2005;  15 460-466
  • 20 Grosso L M, Triche E W, Belanger K, Benowitz N L, Holford T R, Bracken M B. Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction.  Am J Epidemiol. 2006;  163 1035-1041
  • 21 Carpenter M W, Coustan D R. Criteria for screening tests for gestational diabetes.  Am J Obstet Gynecol. 1982;  144 768-773
  • 22 Dooley S L, Metzger B E, Cho N, Liu K. The influence of demographic and phenotypic heterogeneity on the prevalence of gestational diabetes mellitus.  Int J Gynaecol Obstet. 1991;  35 13-18
  • 23 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
  • 24 Cohen O, Epstein G S, Weisz B, Homko C J, Sivan E. Longitudinal assessment of insulin sensitivity in pregnancy. Validation of the homeostasis model assessment.  Clin Endocrinol (Oxf). 2006;  64 640-644
  • 25 Holland D T, Godfredsen K A, Page T, Connor J D. Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation.  J Chromatogr B Biomed Sci Appl. 1998;  707 105-110
  • 26 Jeyabalan A, Powers R W, Durica A R, Harger G F, Roberts J M, Ness R B. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.  Am J Hypertens. 2008;  21 943-947
  • 27 Metzger B E, Lowe L P, Dyer A R HAPO Study Cooperative Research Group et al. Hyperglycemia and adverse pregnancy outcomes.  N Engl J Med. 2008;  358 1991-2002
  • 28 Graham T E, Sathasivam P, Rowland M, Marko N, Greer F, Battram D. Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test.  Can J Physiol Pharmacol. 2001;  79 559-565
  • 29 Shi C L. Effects of caffeine and acetylcholine on glucose-stimulated insulin release from islet transplants in mice.  Cell Transplant. 1997;  6 33-37
  • 30 Bruton J D, Lemmens R, Shi C L et al.. Ryanodine receptors of pancreatic beta-cells mediate a distinct context-dependent signal for insulin secretion.  FASEB J. 2003;  17 301-303
  • 31 Parsons W D, Neims A H. Effect of smoking on caffeine clearance.  Clin Pharmacol Ther. 1978;  24 40-45
  • 32 Kalow W, Tang B K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.  Clin Pharmacol Ther. 1991;  49 44-48
  • 33 Benowitz N L. Clinical pharmacology of caffeine.  Annu Rev Med. 1990;  41 277-288
  • 34 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.  JAMA. 2004;  291 2847-2850

S. Katherine LaughonM.D. M.S. 

IRTA Postdoctoral Fellow, Division of Epidemiology, Statistics and Prevention Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development

6100 Executive Blvd., Room 7B03, Rockville, MD 20852

Email: laughonsk@mail.nih.gov

    >